Where innovative Medical Go-To-Market Success is the rule! 

Want to Learn or See More? Click here

Synergistic Marketing, founded in 1990 by Mark Lutvak, is a successful, growing and profitable sales and marketing contracting firm and consultancy. We are dedicated to serving Small Emerging businesses that own or possess Medical Technology or Medical Device IP. We support our clients with a go-to-market strategy that takes advantage of our extensive network of medical industry companies as well as our extensive list of contacts who are our Corporate Partners.

Want to Learn or See More? Click here


Medical Technology and Device News Title

  • May 21, 2018:

    Inari Medical, Inc., announced today the FlowTriever System has received FDA 510(k) clearance for the treatment of pulmonary embolism (“PE”). This clearance makes the FlowTriever System the first and only thrombectomy device cleared by the FDA for the treatment of Pulmomary Embolisms Full Story

  • May 18, 2018:

    Despite the fact that each year 455 men and women per 100,000 patients are diagnosed with cancer (NCI, 2008-2012 data), 1 in 5 cancer patients are still misdiagnosed, further exacerbating the challenges of treatment for clinicians, patients, and their families. Precipio Diagnostics uses advanced diagnostics and personalized medicine to reduce the prevalence of cancer misdiagnosis. Today, Precipio reports a 99% accuracy rate in correctly diagnosing cancer patients through the company’s unique combination of offerings. Full Story

  • May 17, 2018:

    The NFL (National Football League), having been convinced of the danger of head impacts on its players and the sport overall, has begun a number of initiatives to try to deal with concussions and related injuries. As part of their Play Smart. Play Safe. campaign, the league is releasing a software toolkit to make it easier to design new helmets and to integrate new technologies into helmet design. Full Story

  • May 14, 2018:

    Creative Medical Technology Holdings, a Phoenix, Arizona firm, has filed for a patent for its AmnioStem amniotic fluid derived stem cell therapy for treatment of stroke. According to the company, “The patent application covers the use of the Company’s newly licensed AmnioStem stem cell as a production means for generation of nanoparticles termed “exosomes,” which regenerate damaged brain tissue after stroke.” Full Story